Skip to main
TIL
TIL logo

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc., as a clinical-stage biopharmaceutical company, is advancing its innovative cell therapy pipeline focused on autologous tumor infiltrating lymphocyte (TIL) therapies, which hold promise for treating various solid tumors, including ovarian and renal cancers. The development of ITIL-306, featuring a CoStAR molecule that targets tumor-associated antigens, signifies a strategic position in the evolving oncology landscape, potentially driving growth. As investor confidence strengthens in the oncology sector, there is potential for broader positive implications for Instil Bio's TIL therapies, particularly as preclinical results and upcoming trials continue to validate their efficacy within the biopharmaceutical marketplace.

Bears say

Instil Bio Inc faces significant challenges in advancing its clinical-stage cell therapy candidates, highlighted by concerns over delays in clinical assessments and the potential for unfavorable clinical outcomes, particularly with the AXN-2510 therapy in non-small cell lung cancer and small cell lung cancer. The observation of similar overall survival (OS) curves before and after recent updates has led to skepticism among bearish investors, emphasizing a perceived lack of meaningful progress. Additionally, there is an ongoing risk of dilution in the medium to long term, which could further impact investor sentiment and stock performance.

Instil Bio (TIL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Instil Bio (TIL) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.